Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib plus Phesgo as maintenance therapy in PIK3CA-mutated HER2-positive advanced breast cancer
jRCT2031250577Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Inavolisib + Phesgo maintenance with Placebo + Phesgo maintenance (2 arms). Primary endpoint: Investigator-Assessed Progression-Free Survival (PFS). Started Mar 2026; status: recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031250577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250577.